Scaling Liquid Biopsy Biomarker Discovery: multi-center, Analytical Validation of high resolution ctDNA Profiling Using TSO500 ctDNA v2.0 on NovaSeq X Plus

April 20, 2026

Scaling Liquid Biopsy Biomarker Discovery: multi-center, Analytical Validation of high resolution ctDNA Profiling Using TSO500 ctDNA v2.0 on NovaSeq X Plus

Scaling Liquid Biopsy Biomarker Discovery: multi-center, Analytical Validation of high resolution ctDNA Profiling Using TSO500 ctDNA v2.0 on NovaSeq X Plus

April 20, 2026

Scaling Liquid Biopsy Biomarker Discovery: multi-center, Analytical Validation of high resolution ctDNA Profiling Using TSO500 ctDNA v2.0 on NovaSeq X Plus

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

March 3, 2026

Pierre Gontard1, Nathalie Bernard1, Sara Diels1, Bart Tegenbos1, Dirk Goossens1, Lien Heyrman1, Magdalena Stolarek-Januszkiewicz2, Sam Abujudeh2, Jurgen Del Favero1,Barnaby Balmforth2

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

March 3, 2026

Pierre Gontard1, Nathalie Bernard1, Sara Diels1, Bart Tegenbos1, Dirk Goossens1, Lien Heyrman1, Magdalena Stolarek-Januszkiewicz2, Sam Abujudeh2, Jurgen Del Favero1,Barnaby Balmforth2

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

March 3, 2026

Luca Genovesi, Laurence Mayrand Provencher, Nick Dupuis, Gwenael Pottiez

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

March 3, 2026

Luca Genovesi, Laurence Mayrand Provencher, Nick Dupuis, Gwenael Pottiez

Patient-Centric Measurement of M-Protein Using High-Resolution Intact Mass Spectrometry

Can Microsampling Devices Coupled with Intact Mass High-Resolution Mass Spectrometry Improve M-Protein Monitoring and Simplify Minimal Residual Disease Assessment in Multiple Myeloma?

November 10, 2025

Can Microsampling Devices Coupled with Intact Mass High-Resolution Mass Spectrometry Improve M-Protein Monitoring and Simplify Minimal Residual Disease Assessment in Multiple Myeloma?

Can Microsampling Devices Coupled with Intact Mass High-Resolution Mass Spectrometry Improve M-Protein Monitoring and Simplify Minimal Residual Disease Assessment in Multiple Myeloma?

November 10, 2025

Can Microsampling Devices Coupled with Intact Mass High-Resolution Mass Spectrometry Improve M-Protein Monitoring and Simplify Minimal Residual Disease Assessment in Multiple Myeloma?

Artificial Intelligence-powered Spatial Analysis of Tumor Microenvironment Identifies Immune Phenotype in Non- Small Cell Lung Cancer, Colorectal Cancer and Urothelial Cancer.

October 30, 2025

Elizabeth Ross1, Chang Ho Ahn2, Seungeun Lee2, Sanghoon Song2, Yannick Waumans1, Nicholas Dupuis1, Mark Kockx1

Artificial Intelligence-Powered Spatial Analysis of Tumor Microenvironment Identifies Immune Phenotype in Non-Small Cell Lung Cancer, Colorectal Cancer and Urothelial Cancer.

Artificial Intelligence-powered Spatial Analysis of Tumor Microenvironment Identifies Immune Phenotype in Non- Small Cell Lung Cancer, Colorectal Cancer and Urothelial Cancer.

October 30, 2025

Elizabeth Ross1, Chang Ho Ahn2, Seungeun Lee2, Sanghoon Song2, Yannick Waumans1, Nicholas Dupuis1, Mark Kockx1

Artificial Intelligence-Powered Spatial Analysis of Tumor Microenvironment Identifies Immune Phenotype in Non-Small Cell Lung Cancer, Colorectal Cancer and Urothelial Cancer.